大动脉炎中西医协同分期诊疗的研究进展

Research progress on diagnosis and treatment of Takayasu arteritis:the integration strategy of traditional Chinese and Western medicine based on disease stages

大动脉炎(Takayasu arteritis,TAK)是一种慢性非特异性血管炎,西医治疗包括糖皮质激素、免疫抑制剂及生物靶向药,但存在诱导缓解率低、血管病变持续进展的难题。中医学中大动脉炎属于“脉痹”范畴,中医对该病在缓解临床症状,提高生存质量,改善预后及预防复发方面有着不可替代的作用。本文综述了大动脉炎发病机制、医家学说及临床经验,提出了减毒增效理论,并基于大动脉炎分期进行病证结合探讨,形成大动脉炎“病证结合”中西医协同诊疗特色,为改善患者远期预后提供新的治疗模式和策略。

Takayasu arteritis(TAK)is a kind of chronic non-specific vasculitis.It is commonly treated with glucocorticoids,immunosuppressants and biologic and targeted agents.However,there are still problems of low disease remission rate and continuous progression of vascular lesions.In traditional Chinese medicine,TAK belongs to the category of“pulse bi”.Traditional Chinese medicine played an irreplaceable role in relieving clinical symptoms,improving life quality and disease prognosis,and preventing recurrence.In this review,the authors summarized the pathogenesis,famous traditional Chinese medicine experts'theories and clinical experiences of TAK.The theory of reducing side effects and enhancing anti-inflammation effects was put forward.Based on the combination of different disease stages and syndromes,we integrated treatments of Chinese and western medicine of TAK,so as to form a new treatment model and strategy for improving long-term prognosis of TAK patients.